Emmaus Life Sciences, Inc. (NASDAQ: EMMA) was founded in 1987, formerly known as MYnd Analytics Inc. (formerly NASDAQ: MYND). In July 2019, it was changed to the current name and the new stock code was activated. The former name was CNS. Response, Inc., changed to MYnd Analytics, Inc. in November 2015, is headquartered in Mission Viejo, California, USA, with 21 full-time employees. It is a predictive analytics company that has developed a set of decision support tools to help doctors reduce mental health aspects Misdiagnosis, and can provide patients with more personalized care.
Emmaus Life Sciences (EMMA):
Emmaus Life Sciences Inc. operates as a clinical predictive analytics company in the United States. The company manages the delivery of remote psychiatry and remote behavioral health services through a network of psychiatrists, psychologists and therapists.
Emmaus Life Sciences is commercializing its psychiatric electroencephalogram (EEG) evaluation registry predictive analysis tool to help doctors reduce mental health trials and error treatments.
The Emmaus Life Sciences technology platform uses complex algorithms to analyze EEG to generate psychiatric EEG assessment registration reports to predict individual responses to a series of drugs for the treatment of behavioral disorders, including depression, anxiety, bipolar disorder, and post-traumatic stress Barriers, and other non-mental diseases.
On January 7, 2019, MYnd Analytics and Emmaus Life Sciences announced the merger and spin-off transaction:
Predictive analytics company MYnd Analytics, a company that aims to improve the delivery of mental health services through the combination of telemedicine and data analysis, today announced that it has reached a definitive share merger agreement with Emmaus Life Sciences, Inc., the latter being Sickle Cell Leader in disease treatment. According to the merger agreement, Emmaus Life Sciences will become a wholly-owned subsidiary of MYnd Analytics in exchange for MYnd Analytics to issue additional ordinary shares to Emmaus shareholders and other shareholders. After the merger, the original shareholders of Emmaus will own approximately 94% of the ordinary shares of MYnd Analytics. It is expected that the combined company will be named after Emmaus related words and will use the new stock trading code.
On July 18, 2019, MYnd Analytics changed its name to Emmaus Life Sciences and started trading with the code EMMA instead of the original code MYND.